Health

CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting

SHANGHAI, Jan. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2024 American Society of Clinical Oncology Gastrointestin...

2024-01-19 21:50 1816

Harbour BioMed Announces Positive Profit Alert

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 18, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2024-01-19 12:52 5374

Datasea Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

BEIJING, Jan. 18, 2024 /PRNewswire/ -- Datasea Inc., a Nevada corporation (NASDAQ: DTSS) ("Datasea" or the "Company"), which engages in the business segments of U.S.-based intelligent acoustics andChina-based 5G messaging technology, today announced that the Company's Board of Directors has appro...

2024-01-19 05:39 3749

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

HIGHLIGHTS * The US FDA has cleared Amplia's Investigational New Drug (IND) Application for a clinical trial of narmafotinib in theUSA * The proposed trial would explore the combination of narmafotinib and FOLFIRINOX in advanced pancreatic cancer patients in theUSA MELBOURNE, Australia ,Jan. ...

2024-01-18 10:31 1290

Lunit INSIGHT CXR Excels in Lung Nodule Detection - Exceptional Performance in Head-to-Head Study published in Radiology

- Lunit's AI-powered chest X-ray analysis solution shows highest AUC of 0.93 in a recent multi-center, multi-use case, multi-vendor lung nodule detection study SEOUL, South Korea, Jan. 17, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostic...

2024-01-17 22:15 1621

Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)

SUZHOU, China, and ROCKVILLE, Md., Jan. 16, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that olverembatinib (R&D Code: HQP1351) has been ...

2024-01-17 12:10 4093

WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

SHANGHAI, Jan. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that a patent for WuXiBodyTM – a proprietary, highly flexible engineering platform that greatly enhances the deve...

2024-01-17 08:30 4018

Health In Tech Takes Center Stage at Greek House Annual Meeting at the World Economic Forum 2024 in Davos, Showcasing Innovation and Leadership

STUART, Fla., Jan. 16, 2024 /PRNewswire/ -- Health In Tech, an industry-leading insurtech company that delivers disruptive innovation and re-imagines self-funded health plans, is set to make waves at the Greek House Annual Meeting at the Greek House Annual Meeting at the World Economic Forum 2024...

2024-01-17 00:32 1750

Lunit AI Solutions to Power Samsung's X-ray Devices for Advanced Chest Screening

* Three-year supply contract: Lunit INSIGHT CXR and Lunit INSIGHT CXR Triage to enhance lung abnormality detection in Samsung's premium X-ray devices SEOUL, South Korea, Jan. 16, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and t...

2024-01-16 22:04 1898

Complete Genomics and Gencove Announce agreement at Plant and Animal Genome Conference (PAG 31) to offer a bundled solution for low-pass whole genome sequencing

SAN JOSE, Calif., Jan. 16, 2024 /PRNewswire/ -- Complete Genomics , a life sciences company that provides novel, end-to-end DNA sequencing solutions, today announced a joint marketing agreement withGencove,  a pioneer of low-pass whole gen...

2024-01-16 22:00 1567

Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors

CHENGDU, China, Jan. 16, 2024 /PRNewswire/ -- Chengdu Chipscreen NewWay Biosciences Co., Ltd. (NewWay) announced that onJanuary 5, 2024, the dosing of the first patient for a phase I clinical trial of a PD-1/CD40 bispecific antibody (bsAb), NWY001, at Sun Yat-Sen University Cancer Center inChina,...

2024-01-16 17:00 1905

PranaQ to Unveil Revolutionary Sleep Tech at CES 2024: Introducing TipTraQ, the AI Sleep Tracking and Improvement Solution

NEW YORK, Jan. 15, 2024 /PRNewswire/ -- PranaQ, the innovative sleep tech startup, has made waves at CES 2024 with the highly anticipated launch of its flagship product, TipTraQ. This cutting-edge device goes beyond traditional sleep monitoring, offering a comprehensive solution for diagnosing an...

2024-01-16 00:00 1557

CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection

SHANGHAI, Jan. 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that CT011, an autologous CAR T-cell product candidate against Glypic...

2024-01-15 21:50 1765

Positive Outcome from a Phase Ib Study in Australia Treating Patients with Androgenic Alopecia

SHANGHAI, Jan. 14, 2024 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical-stage innovative biopharmaceutical company, announced recently that the company has completed a Phase Ib study, "An Open-Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgene...

2024-01-15 08:08 1636

RingConn Smart Ring Impresses at CES 2024: Unveiling Plans on Features and Medical Algorithms Updates that Redefine Personal Health Management

Boasting 24/7 health monitoring with superior comfort and accuracy, the smart ring underlies RingConn's commitment to advancing the intersection of healthcare and technology LAS VEGAS, Jan. 12, 2024 /PRNewswire/ -- RingConn , a leading personal health technology compa...

2024-01-13 12:11 2131

San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry

SAN FRANCISCO, Jan. 12, 2024 /PRNewswire/ -- Every January, the global medical health and financial investment sectors turn their focus toSan Francisco. The J.P. Morgan Healthcare Conference has been successfully held here for 42 editions, becoming a hall where industry thought converges and spar...

2024-01-12 23:28 6225

Qilian International Holding Group Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule

JIUQUAN, China, Jan. 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ: QLI ) ("Qilian" or the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that onJanuary 10, 2024,...

2024-01-12 20:30 5484

ClinChoice Acquires CSI, Expanding its Global Footprint into Southeast Asia

SHANGHAI, PHILADELPHIA and SINGAPORE, Jan. 11, 2024 /PRNewswire/ -- ClinChoice, a leading global Contract Research Organization (CRO), today announced expanding its global footprint with the acquisition of CSI Medical Research (CSI). CSI is a regional clinical CRO with professional staff and part...

2024-01-12 11:00 2797

United Imaging Intelligence Highlights Dedications to Advancing Intelligent Healthcare at RSNA Conference 2023

BOSTON, Jan. 11, 2024 /PRNewswire/ -- The Radiological Society of North America (RSNA) has concluded its annual meeting inChicago, IL, serving as a platform for revolutionary advancements in the field of radiology. United Imaging Intelligence (UII), an innovative subsidiary of United Imaging Grou...

2024-01-11 22:00 1378

GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia

SHANGHAI, Jan. 11, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology, announced that U.S. Food and Drug Administration (FDA) has recently granted another two designations for SLS009 (GFH009). GFH009 (hig...

2024-01-11 19:00 1794
1 ... 40414243444546 ... 273